BioMedNewsBreaks – XSurgical Schedules Webinar to Report Quarter Results, Progress

XSurgical, an artificial intelligence surgical robotics company, is hosting an upcoming webinar to report on the company’s quarterly progress and major achievements. Slated for Aug. 24, 2023, at 9 a.m. PST, the webinar will feature key XSurgical leaders, including cofounder and CEO Dr. Gianluca De Novi, board chair Michele Marzola and board of advisors member Arnon Krongrad. XSurgical is bringing an innovative, unique approach to the surgical robotics industry as it focuses on its mission to democratize surgical robotics by creating a versatile platform accessible to a much wider population worldwide. The company is working to increase the quality and number of robotic procedures available by creating a modular, open-architecture surgical robot. 

To view the webinar, visit https://ibn.fm/foUfO

To view the full press release, visit https://ibn.fm/A9DuV

About XSurgical

XSurgical’s system uses AI and machine learning to perform a range of procedures with precision and accuracy, while remaining affordable and easily deployable. By aiming to offer these solutions, XSurgical is working toward making surgical robotics more cost effective, efficient and accessible, thereby improving patient outcomes and increasing the utilization of surgical robots in a variety of environments. For more information, visit the company’s website at www.XSurgicalRobotics.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended…

3 days ago

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a…

3 days ago

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

4 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and…

5 days ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial

Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, announced the publication of…

6 days ago

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced…

7 days ago